US 2022/0187315 A1 · METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION

Methods and compositions for diagnosing depression

AssigneesThe University of Arkansas for Medical Sciences, Rush Medical College, Mayo Clinic, Emory University School of Medicine, University of Hawaii Cancer Center

InventorsRima F. Kaddurah-Daouk, Augustus John Rush, Jr., Siamak Mahmoudian Dehkordi, Sudeepa Bhattcharyya, Ranga R. Krishnan, Mark A. Frye, Ahmed T. Ahmed, Richard M. Weinshilboum, Boadie W. Dunlop, Wei Jia

Life of this patent

Estimating the term…

Abstract

Described herein are methods and composition for diagnosing and evaluating the treatment of depression using one or more biomarker metabolites for the diagnosis and monitoring treatment efficacy. In one aspect, the biomarker metabolites can be used to screen subjects for the likelihood of developing depression, the diagnosis thereof, monitoring the efficacy of treatment, and evaluating a subject's propensity for responding to treatment.

Claims119

Dependent claims

A method for diagnosing or detecting depression in a subject, the method comprising:

obtaining a sample from a subject and determining concentration levels of one or more biomarker metabolites in the sample from the subject;
and
diagnosing the subject as having depression or an increased risk of depression when the concentration levels of the one or more biomarker metabolites in the sample from the subject is different from (greater or less) than concentration levels the one or more biomarker metabolites in a control sample.

A method of treating depression and evaluating the treatment efficacy comprising:

identifying a subject suffering from or at risk of developing depression;
administering an effective amount sufficient to attenuate, reduce, or eliminate the symptoms of depression of one or more antidepressants, cognitive behavior therapy, exercise, dietary supplements, prebiotics, probiotics, or dietary changes, or a combination thereof over a period of time;
obtaining a sample from the subject and evaluating concentration levels of one or more biomarker metabolites;
evaluating the concentration level of the one or more biomarker metabolites in comparison to control concentration levels of the one or more biomarker metabolites;
evaluating the efficacy of the depression treatment;
and
continuing the administration one or more first depression treatments;
administering an additional depression treatment;
or administering one or more second depression treatments (switching the treatment regimen).

6 more elements

A method of evaluating the efficacy of depression treatment, the method comprising:

identifying a subject suffering from or at risk of developing depression;
obtaining a sample from the subject and determining concentration levels of one or more biomarker metabolites in the sample from the subject;
and
diagnosing the subject as having depression or an increased risk of depression when the concentration levels of the one or more biomarker metabolites in the sample from the subject is different from (greater or less) than the concentration levels the one or more biomarker metabolites in a control sample.
administering an effective amount sufficient to attenuate, reduce, or eliminate the symptoms of depression of one or more first depression treatments over a period of time;
obtaining an additional sample from the subject and reevaluating the concentration level of the one or more biomarker metabolites in comparison to the subject's initial concentration levels of the one or more biomarker metabolites and the control concentration levels of the one or more biomarker metabolites;
evaluating the efficacy of the depression treatment;
and
continuing the one or more first depression treatments, administering an additional depression treatment, or administering one or more second depression treatments (switching the treatment regimen).

6 more elements

A method for screening a subject for depression or an increased risk of depression, the method comprising:

obtaining a sample from the subject and determining concentration levels of one or more biomarker metabolites in the sample from the subject;
and
diagnosing the subject as having depression or an increased risk of depression when the concentration levels of the one or more biomarker metabolites in the sample from the subject is different from (greater or less) than the concentration levels the one or more biomarker metabolites in a control sample.

A method for predicting a depression subject's propensity of treatment success (depression remission) in response to an antidepressant, the method comprising:

obtaining a sample from the subject and evaluating the concentration level of the one or more biomarker metabolites in comparison to the control concentration levels of the one or more biomarker metabolites;
administering an effective amount sufficient to attenuate, reduce, or eliminate the symptoms of depression of one or more antidepressants, cognitive behaviorial therapy, or a combination thereof for a period of time;
obtaining an additional sample from the subject and evaluating the concentration level of the one or more biomarker metabolites in comparison to the subject's initial concentration levels of the one or more biomarker metabolites and the control concentration levels of the one or more biomarker metabolites;
continuing the one or more initial depression treatments, administering an additional depression treatment, or administering one or more second depression treatments (switching the treatment regimen).

1 more element

A method for evaluating a depression subject's response to an antidepressant treatment, cognitive behavioral therapy or a combination thereof, the method comprising:

obtaining a sample from the subject and evaluating the concentration level of the one or more biomarker metabolites in comparison to the control concentration levels of the one or more biomarker metabolites;
administering an effective amount sufficient to attenuate, reduce, or eliminate the symptoms of depression of one or more antidepressants, cognitive behaviorial therapy, or a combination thereof for a period of time;
obtaining an additional sample from the subject and evaluating the concentration level of the one or more biomarker metabolites in comparison to the subject's initial concentration levels of the one or more biomarker metabolites and the control concentration levels of the one or more biomarker metabolites;
evaluating the efficacy of the initial depression treatment;
and
continuing the one or more initial depression treatments, administering an additional depression treatment, or administering one or more second depression treatments (switching the treatment regimen).

3 more elements

A method for differentiating a depression subject's depression phenotype, the method comprising:

identifying a subject experiencing depression or at risk of depression;
obtaining a sample from the subject and evaluating the concentration level of the one or more biomarker metabolites in comparison to the control concentration levels of the one or more biomarker metabolites;
administering an effective amount sufficient to attenuate, reduce, or eliminate the symptoms of depression of one or more antidepressants, cognitive behaviorial therapy, or a combination thereof for a period of time;
obtaining an additional sample from the subject and evaluating the concentration level of the one or more biomarker metabolites in comparison to the subject's initial concentration levels of the one or more biomarker metabolites and the control concentration levels of the one or more biomarker metabolites;
evaluating the phenotype and efficacy of the initial depression treatment;
and
continuing the one or more initial depression treatments, administering an additional depression treatment, or administering one or more second depression treatments (switching the treatment regimen).

4 more elements

Dependencies are inferred from the claim text.